The Effects and Neural Mechanisms of Vitamin D and Iron-Immune Homeostasis on Inhibitory Control in Obsessive-Compulsive Disorder

NCT07763977 · tracked via the Priya Life Science China tracker

Sponsor

Guangdong Provincial People's Hospital

Phase

Not applicable

Started

2024-08-06

Last updated

2026-08-13

Condition(s) studied

Obsessive Compulsive Disorder (OCD)

Investigational drug(s) / intervention(s)

Calcitriol and Iron Supplements

Calcitriol and Iron Supplements: In addition to participants' existing medication regimens, calcitriol and iron supplements will be added.

Study summary

This study is a randomized, open-labled, no-treatment-controlled clinical trial designed to investigate the effects of vitamin D and iron-immune homeostasis on inhibitory control and the underlying neural mechanisms in patients with obsessive-compulsive disorder (OCD). Participants will be patients with OCD who meet the study eligibility criteria.

The study's primary aim is to compare changes in glutamate and related metabolite concentrations within the anterior cingulate-thalamic circuit, inhibitory control performance, peripheral immune markers, and clinical symptoms before and after treatment with calcitriol and iron polysaccharide complex. The study will also investigate the neural-circuit mechanisms underlying inhibitory control deficits in patients with OCD and their changes following the interventions. These objectives will be addressed using resting-state Magnetic Resonance Spectroscopy(MRS), inhibitory control tasks, peripheral blood immune-marker measurements, and clinical symptom assessments.

The primary hypothesis is that inhibitory control deficits in patients with OCD are associated with dysregulated glutamatergic metabolism in the anterior cingulate-thalamic circuit. Vitamin D and iron supplementation are hypothesized to promote the balance of glutamate and related metabolites within this circuit, regulate immune homeostasis, and improve inhibitory control deficits in patients with OCD.

Eligibility

Sex

ALL

Min age

14 Years

Max age

45 Years

Healthy volunteers

Inclusion Criteria: 1. Meet the DSM-5 diagnostic criteria for obsessive-compulsive disorder (OCD); 2. Have a total score of ≥16 on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) and a total score of \<17 on the 17-item Hamilton Depression Rating Scale (HAMD-17); 3. Have a disease duration of ≥1 year and be between 14 and 50 years of age; 4. Be right-handed and have completed at least junior high school education; and 5. Fully understand the study procedures, be willing and able to participate in and complete the entire study, and provide written informed consent. Exclusion Criteria: 1. Presence of a neurological disorder or serious medical condition; 2. Pregnancy or breastfeeding; 3. A history of alcohol or substance abuse or dependence; 4. A history of seizures; 5. A diagnosis of a major psychotic disorder or bipolar disorder; 6. A diagnosis of depressive disorder; 7. Any contraindication to magnetic resonance imaging (MRI); 8. Use of iron or vitamin D supplements within the previous 6 months, or use of corticosteroids for any reason within the previous 3 months; or 9. Presence of an acute or chronic systemic disease that may affect iron or vitamin D levels, including, but not limited to, hypothyroidism, hyperthyroidism, hypoparathyroidism, hyperparathyroidism, diabetes mellitus, clinically active infection, or iron-deficiency anemia.

Primary outcome measure(s)

Change from Baseline in Neurometabolite Concentrations in Key Brain Regions — Baseline, Post-treatment (Week 12)
Change from baseline to Week 12 in the concentrations of Glutamate (Glu), Glutamate+Glutamine (Glx), and Glutathione (GSH) within two pre-specified regions of interest: the thalamus and the anterior cingulate cortex (ACC). Levels are measured in both resting and functional states using Magnetic Resonance Spectroscopy (MRS).
Change from Baseline in Inhibitory Control Performance — Baseline, Post-treatment (Week 12)
Change from baseline to Week 12 in inhibitory control performance, as measured by the error rate on a Go-Nogo task.

Trial sites (1)

Facility	City	Region	Status
Guangdong Mental Health Center, Guangdong Provincial People's Hospital	Guangzhou	Guangdong

More Guangdong Provincial People's Hospital trials in China

Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC Recruiting

Safety and Effectiveness of Early Aspirin Administration After Mitral Valve Repair Recruiting

NAC for Treatment-Resistant OCD and Other Related Disorders Active, not recruiting

Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial Starting soon

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC Active, not recruiting

Other trials for the same condition

NAC for Treatment-Resistant OCD and Other Related Disorders Active, not recruiting

Exploring the Efficacy of Accelerated Transcranial Direct Current Stimulation (tDCS) as Adjunct to Pharmacotherapy in the Treatment of Obsessive-compulsive Disorder Starting soon

Accelerated rTMS Therapeutic Approach for Refractory Obsessive-Compulsive Disorder Recruiting

Efficacy and Mechanism of Augmentation of Cognitive Behavioral Therapy With Transcranial Alternating Current Stimulation(tACS) for Obsessive-Compulsive Disorder (OCD) Recruiting

Transcutaneous Electrical Acupoint Stimulation Combined With Exposure and Response Prevention in the Treatment of Patients With Obsessive-Compulsive Disorder: A Randomized Controlled Trial Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07763977 on ClinicalTrials.gov ↗ ← All trials in China